Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Lorlatinib
Cat. No.:
0225LY-0786
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Lorlatinib is an orally available, ATP-competitive inhibitor of Ros1 and anaplastic lymphoma kinase (ALK) with potential antineoplastic use.
Synonym:
1454846-35-5; Lorbrena; (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile; 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-; 7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile; (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile; (R)-26-Amino-55-fluoro-11,4,7-trimethyl-6-oxo-11H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-15-carbonitrile
CAS No.:
1454846-35-5
Compound CID:
71731823
Formula:
C21H19FN6O2
Formula Weight:
406.41
Specification
Targets&IC50:
ALK (L1196M): 0.07 nM(Ki); FER: 3.3 nM; ROS1: <0.02 nM(Ki); TYK1/LTK: 2.7 nM; ALK: <0.07 nM(Ki)
Relative Density:
1.42 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Lorlatinib can be used in neuro-oncology research to evaluate its brain-penetrant properties and selective inhibition of ALK and ROS1.
Library Information
Target:
ALK; Tyrosine kinases
Receptor:
ALK; ALK (L1196M); LTK (TYK1)
Pathways:
Immunology/Inflammation; Apoptosis; Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-11
Plate Location:
b5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
13 mg/mL; 31.99 mM
Ethanol Max Solubility:
40.6 mg/mL; 99.9 mM
